# Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

> **NCT00138619** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 478 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** vildagliptin

## Key facts

- **NCT ID:** NCT00138619
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138619, "Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00138619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*